Network Meta-Analysis In The Evaluation of Vaccines

BACKGROUND: Head-to-head clinical efficacy randomized controlled trials (RCTs) for vaccines are often unfeasible due to logistical and/or ethical constraints and comparative real-world effectiveness studies are methodologically challenging. Without direct efficacy or effectiveness comparisons, relat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Value in health 2017-10, Vol.20 (9), p.A777
Hauptverfasser: McGirr, A, Widenmaier, R, Burnett, H, Curran, D, Espie, E, Mrkvan, T, Oostvogels, L, Simone, B, McElhaney, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 9
container_start_page A777
container_title Value in health
container_volume 20
creator McGirr, A
Widenmaier, R
Burnett, H
Curran, D
Espie, E
Mrkvan, T
Oostvogels, L
Simone, B
McElhaney, J
description BACKGROUND: Head-to-head clinical efficacy randomized controlled trials (RCTs) for vaccines are often unfeasible due to logistical and/or ethical constraints and comparative real-world effectiveness studies are methodologically challenging. Without direct efficacy or effectiveness comparisons, relative risk/benefit of vaccines can be challenging to assess. OBJECTIVES: While network meta-analyses (NMAs) have been used extensively to estimate the comparative efficacy and safety of therapeutic interventions, the application of this method to compare vaccines is rare. To our knowledge, there is only one published vaccine NMA which compares the relative effectiveness of rotavirus vaccines. We discuss how NMAs can be used to evaluate the relative efficacy and safety of vaccines within a specific disease area; using vaccines to prevent herpes zoster (HZ) as another case example. METHODS: NMA methodology can be applied to indirectly compare vaccines; however, issues such as waning immunity, indirect vaccine effect, changing epidemiology over time, and seasonality of the disease of interest pose unique challenges. Detailed feasibility assessments should be undertaken to systematically determine if NMA is appropriate from a methodological and clinical perspective. This requires close collaboration between methodologists and clinical experts. Recently, a comparison of vaccines for HZ was deemed feasible, in particular due to availability of evidence studied in large, well-designed RCTs, and due to the epidemiology of HZ. Key challenges faced included variations in effect modifiers such as patient age, follow-up duration, and outcome definitions. It was possible to leverage existing NMA guidance to provide credible and reliable estimates of the relative effect of HZ vaccines that have not been studied in head-to-head efficacy trials. CONCLUSIONS: NMAs provide a method to indirectly compare different medical interventions, including vaccines, in the absence of head-to-head data. With RCT data and real world evidence, NMAs can contribute to inform vaccine recommendations and public health decision making.
doi_str_mv 10.1016/j.jval.2017.08.2244
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2113728385</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2113728385</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1674-46d68a2f95da0dd00d1844300b7cb6deeffa21f75f1a8e3808c29a0e169454a83</originalsourceid><addsrcrecordid>eNotkE9Lw0AUxBdRsFY_gZeA58T39l82x1KqFqpeqtflNdnFxJrU3UTptzehnmYOw8zwY-wWIUNAfd9kzQ_tMw6YZ2AyzqU8YzNUXKYyF-J89FCYVACqS3YVYwMAWnA1Y-LF9b9d-EyeXU_poqX9MdYxWbfJ9sMlq7F1oL7u2qTzyTuVZd26eM0uPO2ju_nXOXt7WG2XT-nm9XG9XGzSEnU-LutKG-K-UBVBVQFUaKQUALu83OnKOe-Jo8-VRzJOGDAlLwgc6kIqSUbM2d2p9xC678HF3jbdEMaL0XJEkXMjjBpT4pQqQxdjcN4eQv1F4WgR7ETHNnaiYyc6Foyd6Ig_Sk1XnQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2113728385</pqid></control><display><type>article</type><title>Network Meta-Analysis In The Evaluation of Vaccines</title><source>Applied Social Sciences Index &amp; Abstracts (ASSIA)</source><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>McGirr, A ; Widenmaier, R ; Burnett, H ; Curran, D ; Espie, E ; Mrkvan, T ; Oostvogels, L ; Simone, B ; McElhaney, J</creator><creatorcontrib>McGirr, A ; Widenmaier, R ; Burnett, H ; Curran, D ; Espie, E ; Mrkvan, T ; Oostvogels, L ; Simone, B ; McElhaney, J</creatorcontrib><description>BACKGROUND: Head-to-head clinical efficacy randomized controlled trials (RCTs) for vaccines are often unfeasible due to logistical and/or ethical constraints and comparative real-world effectiveness studies are methodologically challenging. Without direct efficacy or effectiveness comparisons, relative risk/benefit of vaccines can be challenging to assess. OBJECTIVES: While network meta-analyses (NMAs) have been used extensively to estimate the comparative efficacy and safety of therapeutic interventions, the application of this method to compare vaccines is rare. To our knowledge, there is only one published vaccine NMA which compares the relative effectiveness of rotavirus vaccines. We discuss how NMAs can be used to evaluate the relative efficacy and safety of vaccines within a specific disease area; using vaccines to prevent herpes zoster (HZ) as another case example. METHODS: NMA methodology can be applied to indirectly compare vaccines; however, issues such as waning immunity, indirect vaccine effect, changing epidemiology over time, and seasonality of the disease of interest pose unique challenges. Detailed feasibility assessments should be undertaken to systematically determine if NMA is appropriate from a methodological and clinical perspective. This requires close collaboration between methodologists and clinical experts. Recently, a comparison of vaccines for HZ was deemed feasible, in particular due to availability of evidence studied in large, well-designed RCTs, and due to the epidemiology of HZ. Key challenges faced included variations in effect modifiers such as patient age, follow-up duration, and outcome definitions. It was possible to leverage existing NMA guidance to provide credible and reliable estimates of the relative effect of HZ vaccines that have not been studied in head-to-head efficacy trials. CONCLUSIONS: NMAs provide a method to indirectly compare different medical interventions, including vaccines, in the absence of head-to-head data. With RCT data and real world evidence, NMAs can contribute to inform vaccine recommendations and public health decision making.</description><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1016/j.jval.2017.08.2244</identifier><language>eng</language><publisher>Lawrenceville: Elsevier Science Ltd</publisher><subject>Clinical trials ; Comparative studies ; Data processing ; Decision making ; Efficacy ; Epidemiology ; Experts ; Feasibility ; Herpes zoster ; Immunity ; Intervention ; Leverage ; Meta-analysis ; Public health ; Research methodology ; Risk factors ; Rotavirus ; Shingles ; Therapeutic applications ; Vaccines</subject><ispartof>Value in health, 2017-10, Vol.20 (9), p.A777</ispartof><rights>Copyright Elsevier Science Ltd. Oct/Nov 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1674-46d68a2f95da0dd00d1844300b7cb6deeffa21f75f1a8e3808c29a0e169454a83</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,30999</link.rule.ids></links><search><creatorcontrib>McGirr, A</creatorcontrib><creatorcontrib>Widenmaier, R</creatorcontrib><creatorcontrib>Burnett, H</creatorcontrib><creatorcontrib>Curran, D</creatorcontrib><creatorcontrib>Espie, E</creatorcontrib><creatorcontrib>Mrkvan, T</creatorcontrib><creatorcontrib>Oostvogels, L</creatorcontrib><creatorcontrib>Simone, B</creatorcontrib><creatorcontrib>McElhaney, J</creatorcontrib><title>Network Meta-Analysis In The Evaluation of Vaccines</title><title>Value in health</title><description>BACKGROUND: Head-to-head clinical efficacy randomized controlled trials (RCTs) for vaccines are often unfeasible due to logistical and/or ethical constraints and comparative real-world effectiveness studies are methodologically challenging. Without direct efficacy or effectiveness comparisons, relative risk/benefit of vaccines can be challenging to assess. OBJECTIVES: While network meta-analyses (NMAs) have been used extensively to estimate the comparative efficacy and safety of therapeutic interventions, the application of this method to compare vaccines is rare. To our knowledge, there is only one published vaccine NMA which compares the relative effectiveness of rotavirus vaccines. We discuss how NMAs can be used to evaluate the relative efficacy and safety of vaccines within a specific disease area; using vaccines to prevent herpes zoster (HZ) as another case example. METHODS: NMA methodology can be applied to indirectly compare vaccines; however, issues such as waning immunity, indirect vaccine effect, changing epidemiology over time, and seasonality of the disease of interest pose unique challenges. Detailed feasibility assessments should be undertaken to systematically determine if NMA is appropriate from a methodological and clinical perspective. This requires close collaboration between methodologists and clinical experts. Recently, a comparison of vaccines for HZ was deemed feasible, in particular due to availability of evidence studied in large, well-designed RCTs, and due to the epidemiology of HZ. Key challenges faced included variations in effect modifiers such as patient age, follow-up duration, and outcome definitions. It was possible to leverage existing NMA guidance to provide credible and reliable estimates of the relative effect of HZ vaccines that have not been studied in head-to-head efficacy trials. CONCLUSIONS: NMAs provide a method to indirectly compare different medical interventions, including vaccines, in the absence of head-to-head data. With RCT data and real world evidence, NMAs can contribute to inform vaccine recommendations and public health decision making.</description><subject>Clinical trials</subject><subject>Comparative studies</subject><subject>Data processing</subject><subject>Decision making</subject><subject>Efficacy</subject><subject>Epidemiology</subject><subject>Experts</subject><subject>Feasibility</subject><subject>Herpes zoster</subject><subject>Immunity</subject><subject>Intervention</subject><subject>Leverage</subject><subject>Meta-analysis</subject><subject>Public health</subject><subject>Research methodology</subject><subject>Risk factors</subject><subject>Rotavirus</subject><subject>Shingles</subject><subject>Therapeutic applications</subject><subject>Vaccines</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>7QJ</sourceid><recordid>eNotkE9Lw0AUxBdRsFY_gZeA58T39l82x1KqFqpeqtflNdnFxJrU3UTptzehnmYOw8zwY-wWIUNAfd9kzQ_tMw6YZ2AyzqU8YzNUXKYyF-J89FCYVACqS3YVYwMAWnA1Y-LF9b9d-EyeXU_poqX9MdYxWbfJ9sMlq7F1oL7u2qTzyTuVZd26eM0uPO2ju_nXOXt7WG2XT-nm9XG9XGzSEnU-LutKG-K-UBVBVQFUaKQUALu83OnKOe-Jo8-VRzJOGDAlLwgc6kIqSUbM2d2p9xC678HF3jbdEMaL0XJEkXMjjBpT4pQqQxdjcN4eQv1F4WgR7ETHNnaiYyc6Foyd6Ig_Sk1XnQ</recordid><startdate>201710</startdate><enddate>201710</enddate><creator>McGirr, A</creator><creator>Widenmaier, R</creator><creator>Burnett, H</creator><creator>Curran, D</creator><creator>Espie, E</creator><creator>Mrkvan, T</creator><creator>Oostvogels, L</creator><creator>Simone, B</creator><creator>McElhaney, J</creator><general>Elsevier Science Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QJ</scope></search><sort><creationdate>201710</creationdate><title>Network Meta-Analysis In The Evaluation of Vaccines</title><author>McGirr, A ; Widenmaier, R ; Burnett, H ; Curran, D ; Espie, E ; Mrkvan, T ; Oostvogels, L ; Simone, B ; McElhaney, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1674-46d68a2f95da0dd00d1844300b7cb6deeffa21f75f1a8e3808c29a0e169454a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Clinical trials</topic><topic>Comparative studies</topic><topic>Data processing</topic><topic>Decision making</topic><topic>Efficacy</topic><topic>Epidemiology</topic><topic>Experts</topic><topic>Feasibility</topic><topic>Herpes zoster</topic><topic>Immunity</topic><topic>Intervention</topic><topic>Leverage</topic><topic>Meta-analysis</topic><topic>Public health</topic><topic>Research methodology</topic><topic>Risk factors</topic><topic>Rotavirus</topic><topic>Shingles</topic><topic>Therapeutic applications</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McGirr, A</creatorcontrib><creatorcontrib>Widenmaier, R</creatorcontrib><creatorcontrib>Burnett, H</creatorcontrib><creatorcontrib>Curran, D</creatorcontrib><creatorcontrib>Espie, E</creatorcontrib><creatorcontrib>Mrkvan, T</creatorcontrib><creatorcontrib>Oostvogels, L</creatorcontrib><creatorcontrib>Simone, B</creatorcontrib><creatorcontrib>McElhaney, J</creatorcontrib><collection>CrossRef</collection><collection>Applied Social Sciences Index &amp; Abstracts (ASSIA)</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McGirr, A</au><au>Widenmaier, R</au><au>Burnett, H</au><au>Curran, D</au><au>Espie, E</au><au>Mrkvan, T</au><au>Oostvogels, L</au><au>Simone, B</au><au>McElhaney, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Network Meta-Analysis In The Evaluation of Vaccines</atitle><jtitle>Value in health</jtitle><date>2017-10</date><risdate>2017</risdate><volume>20</volume><issue>9</issue><spage>A777</spage><pages>A777-</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><abstract>BACKGROUND: Head-to-head clinical efficacy randomized controlled trials (RCTs) for vaccines are often unfeasible due to logistical and/or ethical constraints and comparative real-world effectiveness studies are methodologically challenging. Without direct efficacy or effectiveness comparisons, relative risk/benefit of vaccines can be challenging to assess. OBJECTIVES: While network meta-analyses (NMAs) have been used extensively to estimate the comparative efficacy and safety of therapeutic interventions, the application of this method to compare vaccines is rare. To our knowledge, there is only one published vaccine NMA which compares the relative effectiveness of rotavirus vaccines. We discuss how NMAs can be used to evaluate the relative efficacy and safety of vaccines within a specific disease area; using vaccines to prevent herpes zoster (HZ) as another case example. METHODS: NMA methodology can be applied to indirectly compare vaccines; however, issues such as waning immunity, indirect vaccine effect, changing epidemiology over time, and seasonality of the disease of interest pose unique challenges. Detailed feasibility assessments should be undertaken to systematically determine if NMA is appropriate from a methodological and clinical perspective. This requires close collaboration between methodologists and clinical experts. Recently, a comparison of vaccines for HZ was deemed feasible, in particular due to availability of evidence studied in large, well-designed RCTs, and due to the epidemiology of HZ. Key challenges faced included variations in effect modifiers such as patient age, follow-up duration, and outcome definitions. It was possible to leverage existing NMA guidance to provide credible and reliable estimates of the relative effect of HZ vaccines that have not been studied in head-to-head efficacy trials. CONCLUSIONS: NMAs provide a method to indirectly compare different medical interventions, including vaccines, in the absence of head-to-head data. With RCT data and real world evidence, NMAs can contribute to inform vaccine recommendations and public health decision making.</abstract><cop>Lawrenceville</cop><pub>Elsevier Science Ltd</pub><doi>10.1016/j.jval.2017.08.2244</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1098-3015
ispartof Value in health, 2017-10, Vol.20 (9), p.A777
issn 1098-3015
1524-4733
language eng
recordid cdi_proquest_journals_2113728385
source Applied Social Sciences Index & Abstracts (ASSIA); Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals
subjects Clinical trials
Comparative studies
Data processing
Decision making
Efficacy
Epidemiology
Experts
Feasibility
Herpes zoster
Immunity
Intervention
Leverage
Meta-analysis
Public health
Research methodology
Risk factors
Rotavirus
Shingles
Therapeutic applications
Vaccines
title Network Meta-Analysis In The Evaluation of Vaccines
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A17%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Network%20Meta-Analysis%20In%20The%20Evaluation%20of%20Vaccines&rft.jtitle=Value%20in%20health&rft.au=McGirr,%20A&rft.date=2017-10&rft.volume=20&rft.issue=9&rft.spage=A777&rft.pages=A777-&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1016/j.jval.2017.08.2244&rft_dat=%3Cproquest_cross%3E2113728385%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2113728385&rft_id=info:pmid/&rfr_iscdi=true